Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance

Journal of Immunotoxicology

Volumn 9, Issue 2, 2012, Pages 201-209

  Schaalan, Mona F ^a  

^a Egypt   (Egypt)

Author keywords

Adipocyte dysfunction; Adiponectin; High fructose diet; Insulin resistance; Peroxisome proliferator activated receptor ; Statin; Thiazolidinediones; Tumor necrosis factor

Indexed keywords

ADIPONECTIN; FRUCTOSE; PIOGLITAZONE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EPIDIDYMIS FAT; FATTY LIVER; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPOHYPERTROPHY; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ADIPONECTIN; ANIMALS; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FRUCTOSE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIVER; MALE; METABOLIC SYNDROME X; RATS; RATS, WISTAR; SIMVASTATIN; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84861076149     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2012.660998     Document Type: Article

References (65)

1. Astrup, A. and Finer, N. 2000. Redefining Type 2 diabetes: 'Diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev. 1:57-59.
2. Balfour, J. A. and Plosker, G. L. 1999. Rosiglitazone. Drugs. 57:921-30; discussion 931.
3. Bennett, P. H. 1983. The diagnosis of diabetes: New international classification and diagnostic criteria. Annu Rev Med. 34:295-309.
4. Berntorp, K., Trell, E., Thorell, J. and Hood, B. 1983. Relation between plasma insulin and blood glucose in a cross-sectional population study of the oral glucose tolerance test. Acta Endocrinol. 102:549-556.
5. BLIGH, E. G. and DYER, W. J. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 37:911-917.
6. Bogacka, I., Xie, H., Bray, G. A. and Smith, S. R. 2004. The effect of pioglitazone on peroxisome proliferator-Activated receptor-target genes related to lipid storage in vivo. Diabetes Care. 27:1660-1667.
7. Bogacka, I., Xie, H., Bray, G. A. and Smith, S. R. 2005. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes. 54:1392-1399.
8. Bulcao, C., Giuffrida, F. M., Ribeiro-Filho, F. F. and Ferreira, S. R. 2007. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res. 40:229-235.
9. Chu, C. S., Lee, K. T., Lee, M. Y., Su, H. M., Voon, W. C., Sheu, S. H. and Lai, W. T. 2006. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Am J Cardiol. 97:646-650.
10. Colca, J. R., Dailey, C. F., Palazuk, B. J., Hillman, R. M., Dinh, D. M., Melchior, G. W. and Spilman, C. H. 1991. Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes. 40:1669-1674.
11. Devaraj, S., Siegel, D. and Jialal, I. 2007. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol. 100:1397-1399.
12. Ding, S. Y., Shen, Z. F., Chen, Y. T., Sun, S. J., Liu, Q. and Xie, M. Z. 2005. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin. 26:575-580.
13. El Gawly, H. W., Tawfik, M. K., Rashwan, M. E. and Baruzaig, A. S. 2009. The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats. Eur Rev Med Pharmacol Sci. 13:443-451.
14. Esteve, E., Ricart, W. and Fernández-Real, J. M. 2009. Adipocytokines and insulin resistance: The possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care. 32 Suppl 2:S362-S367.
15. Forst, T., Pfutzner, A., Lubben, G., Weber, M., Marx, N., Karagiannis, E., Koehler, C., Baurecht, W., Hohberg, C. and Hanefeld, M. 2007. Effect of simvastatin/pioglitazone on insulin resistance, insulin secretion, adiponectin, and pro-insulin levels in non-diabetic patients at cardiovascular risk-The PIOSTAT Study. Metabolism. 56:491-496.
16. Freed, M. I., Ratner, R., Marcovina, S. M., Kreider, M. M., Biswas, N., Cohen, B. R. and Brunzell, J. D. Rosiglitazone Study 108 investigators. 2002. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes mellitus. Am J Cardiol. 90:947-952.
17. Goldstein, B. J. and Scalia, R. 2004. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 89:2563-2568.
18. González-Sánchez, J. L., Zabena, C. A., Martínez-Larrad, M. T., Fernández-Pérez, C., Pérez-Barba, M., Laakso, M. and Serrano-Ríos, M. 2005. An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res. 13:807-812.
19. Greenberg, A. S. and Obin, M. S. 2006. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 83:461S-465S.
20. Guilherme, A., Virbasius, J. V., Puri, V. and Czech, M. P. 2008. Adipocyte dysfunctions linking obesity to insulin resistance and Type 2 diabetes. Nat Rev Mol Cell Biol. 9:367-377.
21. Guo, Z. and Zhou, L. 2004. Evidence for increased and insulinresistant lipolysis in skeletal muscle of high-fat-fed rats. Metab Clin Exp. 53:794-798.
22. Hajer, G. R., van Haeften, T. W. and Visseren, F. L. 2008. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 29:2959-2971.
23. Hanefeld, M., Marx, N., Pfützner, A., Baurecht, W., Lübben, G., Karagiannis, E., Stier, U. and Forst, T. 2007. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol. 49:290-297.
24. Horio, F., Teradaira, S., Imamura, T., Anunciado, R. V., Kobayashi, M., Namikawa, T. and Niki, I. 2005. The HND mouse, a nonobese model of Type 2 diabetes mellitus with impaired insulin secretion. Eur J Endocrinol. 153:971-979.
25. Hu, E., Liang, P. and Spiegelman, B. M. 1996. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 271:10697-10703.
26. Hwu, C. M., Kwok, C. F., Chen, H. S., Shih, K. C., Lee, S. H., Hsiao, L. C., Lin, S. H. and Ho, L. T. 1999. Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: Results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med. 16:749-754.
27. Ikeda, H., Taketomi, S., Sugiyama, Y., Shimura, Y., Sohda, T., Meguro, K. and Fujita, T. 1990. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung. 40:156-162.
28. Jain, M. K. and Ridker, P. M. 2005. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat Rev Drug Discov. 4:977-987.
29. Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki, K. and Tobe, K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 116:1784-1792.
30. Kakadiya, J. and Shah, N. 2010. Investigation of effects of pioglitazone, glimepiride, nobivolol, valsartan, and hesperidine on glucose, HbA1c and lactate dehydrogenase in isoproterenol-induced myocardial infarction in normal and diabetic rats. JITPS. 1:144-151.
31. Kalo, M. S. 2009. Effect of cholesterol biosynthesis inhibitor on some biochemical parameters in normal male rats. Iraqi J Vet Sci. 23:5-12.
32. Kanda, M., Satoh, K. and Ichihara, K. 2003. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull. 26:1681-1684.
33. Kannappan, S. and Anuradha, C. V. 2009. Insulin sensitizing actions of fenugreek seed polyphenols, quercetin and metformin in a rat model. Indian J Med Res. 129:401-408.
34. Khan, T., Hamilton, M. P., Mundy, D. I., Chua, S. C. and Scherer, P. E. 2009. Impact of simvastatin on adipose tissue: Pleiotropic effects in vivo. Endocrinology. 150:5262-5272.
35. Koh, K. K., Quon, M. J., Lee, S. J., Han, S. H., Ahn, J. Y., Kim, J. A., Chung, W. J., Lee, Y. and Shin, E. K. 2007. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes Care. 30:1605-1607.
36. Lai, I. R., Chang, K. J., Tsai, H. W. and Chen, C. F. 2008. Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction. Transplantation. 85:732-738.
37. Lee, M. Y., Lee, E. Y., Lee, B. J., Won, C. S., Koh, J. H., Shin, J. Y., Shin, Y. G., Cho, B. P. and Chung, C. H. 2007. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med J. 48:301-307.
38. Lumeng, C. N., Bodzin, J. L. and Saltiel, A. R. 2007. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 117:175-184.
39. Majithiya, J. B., Paramar, A. N. and Balaraman, R. 2005. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res. 66:150-161.
40. Malinowski, J. M. and Bolesta, S. 2000. Rosiglitazone in the treatment of Type 2 diabetes mellitus: A critical review. Clin Ther. 22: 1151-68; discussion 1149.
41. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F. and Turner, R. C. 1985. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412-419.
42. Mital, S., Magneson, A., Loke, K. E., Liao, J., Forfia, P. R. and Hintze, T. H. 2000. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol. 36:248-254.
43. Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J. and DeFronzo, R. A. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab. 87:2784-2791.
44. Miyazaki, Y., Mahankali, A., Wajcberg, E., Bajaj, M., Mandarino, L. J. and DeFronzo, R. A. 2004. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in Type 2 diabetic patients. J Clin Endocrinol Metab. 89:4312-4319.
45. Mohamadin, A. M., Elberry, A. A., Abdel Gawad, H. S., Morsy, G. M. and Al-Abbasi, F. A. 2011. Protective effects of simvastatin, a lipid-lowering agent, against oxidative damage in experimental diabetic rats. J. Lipids. 2011:167958. Epub 2011:Dec 6 (doi:10.1155/2011/167958).
46. Moore, M. C., Cherrington, A. D., Mann, S. L. and Davis, S. N. 2000. Acute fructose administration decreases the glycemic response to an oral glucose tolerance test in normal adults. J Clin Endocrinol Metab. 85:4515-4519.
47. Motoshima, H., Wu, X., Sinha, M. K., Hardy, V. E., Rosato, E. L., Barbot, D. J., Rosato, F. E. and Goldstein, B. J. 2002. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: Effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 87:5662-5667.
48. Murdock, D. K., Jansen, D., Juza, R. M., Kersten, M., Olson, K. and Hendricks, B. 2006. Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome. WMJ. 105:22-25.
49. Psyrogiannis, A., Kyriazopoulou, V., Symeonidis, A., Leotsinidis, M. and Vagenakis, A. G. 2003. Relative iron "overload" in offspring of patients with type 2 diabetes mellitus: A new component in the conundrum of insulin resistance syndrome? Hormones (Athens). 2:161-168.
50. Satoh, K., Keimatsu, N., Kanda, M., Kasai, T., Takaguri, A., Sun, F. and Ichihara, K. 2005. HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats. Biol Pharm Bull. 28:2092-2095.
51. Schaefer, J. R., Schweer, H., Ikewaki, K., Stracke, H., Seyberth, H. J., Kaffarnik, H., Maisch, B. and Steinmetz, A. 1999. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis. 144:177-184.
52. Stanhope, K. L. and Havel, P. J. 2008. Fructose consumption: Potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. Curr Opin Lipidol. 19:16-24.
53. Stefan, N., Vozarova, B., Funahashi, T., Matsuzawa, Y., Weyer, C., Lindsay, R. S., Youngren, J. F., Havel, P. J., Pratley, R. E., Bogardus, C. and Tataranni, P. A. 2002. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 51:1884-1888.
54. Stephens, J. M. and Pekala, P. H. 1991. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-Alpha. J Biol Chem. 266:21839-21845.
55. Suganami, T., Tanimoto-Koyama, K., Nishida, J., Itoh, M., Yuan, X., Mizuarai, S., Kotani, H., Yamaoka, S., Miyake, K., Aoe, S., Kamei, Y. and Ogawa, Y. 2007. Role of the Toll-like receptor 4/NF-B pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 27:84-91.
56. Teruel, T., Hernandez, R., Rial, E., Martin-Hidalgo, A. and Lorenzo, M. 2005. Rosiglitazone up-regulates lipoprotein lipase, hormonesensitive lipase and uncoupling protein-1, and down-regulates insulin-induced fatty acid synthase gene expression in brown adipocytes of Wistar rats. Diabetologia. 48:1180-1188.
57. Thorburn, A. W., Storlien, L. H., Jenkins, A. B., Khouri, S. and Kraegen, E. W. 1989. Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr. 49:1155-1163.
58. Vega, G. L., Clark, L. T., Tang, A., Marcovina, S., Grundy, S. M. and Cohen, J. C. 1998. Hepatic lipase activity is lower in African American men than in white American men: Effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC). J Lipid Res. 39:228-232.
59. Vijay, S. K., Mishra, M., Kumar, H. and Tripathi, K. 2009. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in Type-2 diabetes. Acta Diabetol. 46:27-33.
60. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L. and Ferrante, A. W. Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 112: 1796-1808.
61. Westerink, J. and Visseren, F. L. 2011. Pharmacological and nonpharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol. 10:13.
62. Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E. and Tataranni, P. A. 2001. Hypoadiponectinemia in obesity and Type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:1930-1935.
63. Xu, P., Zhang, X. G., Li, Y. M., Yu, C. H., Xu, L. and Xu, G. Y. 2006. Research on the protection effect of pioglitazone for nonalcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B. 7:627-633.
64. Yadav, H., Jain, S., Yadav, M., Sinha, P. R., Prasad, G. B. and Marotta, F. 2009. Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats. Dig Liver Dis. 41:500-508.
65. Yki-Järvinen, H. 2004. Thiazolidinediones. N Engl J Med. 351:1106-1118.